Investigating the Role of Myeloperoxidase and Angiopoietin-like Protein 6 in Obesity and Diabetes

Mohammad G. Qaddoumi 1,2, Muath Alanbaei 3, Maha M. Hammad 1, Irina Al-Khairi 1, Preethi Cherian 1, Arshad Channanath1, Thangavel Alphonse Thanaraj1, Fahd Al-Mulla 4, Mohamed Abu-Farha 1*, and Jehad Abubaker 1*

1 Biochemistry and Molecular Biology, Dasman Diabetes Institute, Kuwait City, Kuwait.
2 Pharmacology and Therapeutics Department, Faculty of Pharmacy, Kuwait University, Kuwait City, Kuwait.
3 Department of Medicine, Faculty of Medicine, Kuwait University, Kuwait City, Kuwait.
4 Functional Genomic Unit, Dasman Diabetes Institute, 15462 Kuwait City, Kuwait;

* Correspondence: jehad.abubakr@dasmaninstitute.org; mohamed.abufarha@dasmaninstitute.org; Tel.: +965 2224-2999

Supplementary Table S1: Association between circulating ANGPTL6 or MPO levels and the outcomes of diabetes and obesity using multivariate logistic regression

|                | T2D AOR [95%CI] | p-value | Obesity AOR [95%CI] | p-value |
|----------------|----------------|---------|---------------------|---------|
| ANGPTL6 (ng/mL)| 1.04 [1.01-1.08] | 0.005   | 1.03[1.01-1.06]     | 0.023   |
| MPO (ng/mL)    | 0.99 [0.98-1.01] | 0.694   | 1.01[0.99-1.02]     | 0.065   |

ANGPTL6: Angiopoietin-like protein 6; AOR: Adjusted odds ratio (adjusted for age and gender); MPO: Myeloperoxidase